Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
Jollibee Plans U.S. Listing for International Business, Shares Rally 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Embraer Boosts Aircraft Deliveries in Q4 2025, Signaling Strong Growth Into 2026 
Lenovo Unveils AI Cloud Gigafactory With NVIDIA and Launches New AI Platform at CES 2026 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Discord Confidentially Files for U.S. IPO, Signaling Major Milestone 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Cancer drug developer Aktis Oncology announced on Thursday that it has successfully priced its upsized U.S. initial public offering at $18 per share, raising approximately $318 million and marking a significant milestone for the biotech company. The IPO gives Aktis a targeted valuation of up to $945.4 million, highlighting strong investor appetite for innovative oncology-focused biotechnology firms despite ongoing volatility in the public markets.
Aktis Oncology focuses on developing next-generation cancer therapies designed to improve outcomes for patients with hard-to-treat tumors. The company’s IPO comes at a time when investor interest in biotechnology and life sciences is gradually rebounding, driven by demand for differentiated pipelines, precision medicine, and novel therapeutic approaches. By upsizing the offering, Aktis demonstrated confidence in its growth strategy and long-term clinical potential.
The IPO priced at the top end of expectations, reflecting robust demand from institutional investors seeking exposure to oncology drug development. Proceeds from the offering are expected to support ongoing clinical trials, research and development activities, and potential expansion of Aktis’ drug pipeline. The capital raise also strengthens the company’s balance sheet as it advances its lead programs toward key regulatory and clinical milestones.
Aktis’ near-billion-dollar valuation places it among notable recent biotech IPOs and underscores the market’s willingness to back companies with compelling science and experienced leadership teams. Analysts note that oncology remains one of the most attractive segments within the pharmaceutical and biotech sectors due to unmet medical needs and the potential for high-value drug approvals.
The successful IPO of Aktis Oncology may encourage other cancer drug developers and biotech startups to consider going public, especially as market conditions stabilize. For investors, the offering signals renewed confidence in innovation-driven biotech companies with strong clinical prospects. As Aktis Oncology begins trading on U.S. markets, attention will remain on its clinical progress, pipeline updates, and ability to deliver long-term value in the competitive cancer drug development landscape.
